Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

solanezumab Articles

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26 April 2013

Lilly plans new trial of Alzheimer's hope solanezumab

13 December 2012

Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development

4 December 2012

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial

11 October 2012

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased

9 October 2012

Mixed news on Lilly's Alzheimer's drug solanezumab; Alimta patent upheld

28 August 2012

Alzheimer’s drug market to triple to $14.3 billion by 2020, says DR

9 October 2011

Alzheimer's drug market to more than triple to $13.3 billion in 2019 in top seven markets, fuelled by new biologic agents

10 September 2010

Double dose of woes for Eli Lilly, as it drops Ph III AD drug semagacestat and FDA panel could say no to expanding use of Cymbalta

18 August 2010

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS